Periodic dialysis in terminal uremia.
D000293:Adolescent; D000328:Adult; D000740:Anemia; D001168:Arthritis / Q000150:complications*; D002648:Child; D005260:Female; D006471:Gastrointestinal Hemorrhage / Q000150:complications*; D005901:Glaucoma / Q000150:complications; D005921:Glomerulonephritis / Q000628:therapy*; D006145:Guanethidine / Q000627:therapeutic use; D006801:Humans; D006830:Hydralazine / Q000627:therapeutic use; D006973:Hypertension / Q000150:complications*; D007239:Infections / Q000150:complications*; D007674:Kidney Diseases / Q000628:therapy*; D008297:Male; D008750:Methyldopa / Q000627:therapeutic use; D008875:Middle Aged; D010493:Pericarditis / Q000150:complications*; D010523:Peripheral Nervous System Diseases / Q000150:complications*; D010530:Peritoneal Dialysis / Q000009:adverse effects*; D007690:Polycystic Kidney Diseases / Q000628:therapy*; D011247:Pregnancy; D011704:Pyelonephritis / Q000628:therapy*; D006435:Renal Dialysis / Q000009:adverse effects*; D012110:Reserpine / Q000627:therapeutic use; D012163:Retinal Detachment / Q000150:complications*; D013927:Thrombosis / Q000150:complications*; D014511:Uremia / Q000628:therapy*; D001745:Urinary Bladder Diseases / Q000628:therapy*; D014652:Vascular Diseases / Q000628:therapy*
D006830:Hydralazine; D008750:Methyldopa; D012110:Reserpine; D006145:Guanethidine